ReviewActa pharmaceutica Sinica. B2022
Optical substrates for drug-metabolizing enzymes: Recent advances and future perspectives.
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Enzyme-Activatable Fluorogenic Probes: Design Strategies, Biomedical Applications, and Future Perspectives.Journal of the American Chemical Society · 2026Review
- Discovery of Sennoside A as a NaturalResearch (Washington, D.C.) · 2026Article
- Discovery of lignans as the effective inhibitors of CES1A alleviate lipid droplets formation.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Functional Imaging of CYP3A4 at Multiple Dimensions Using an AI-Driven High Performance Fluorogenic Substrate.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- A small molecule cryptotanshinone induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway.Acta pharmaceutica Sinica. B · 2025Article
- Photoaffinity probe-enabled discovery of sennoside A reductase inJournal of pharmaceutical analysis · 2025Article
- Recent Progress in Molecular Probes for Imaging of Acute Kidney Injury.Chemical & biomedical imaging · 2024Review
- Unraveling the enigma: housekeeping geneFrontiers in psychiatry · 2024Article
- Enzyme-Based Biosensors and Their Applications.Biosensors · 2023Article
- Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.Acta pharmaceutica Sinica. B · 2023Article
- The role of CYP1A1/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia.Acta pharmaceutica Sinica. B · 2023Article
- Article
- Stimuli-activatable nanomedicine meets cancer theranostics.Theranostics · 2023Review
- The Chinese herb Styrax triggers pharmacokinetic herb-drug interactionsFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-metabolizing enzymes (DMEs), a diverse group of enzymes responsible for the metabolic elimination of drugs and other xenobiotics, have been recognized as the critical determinants to drug safety and efficacy. Deciphering and understanding the key roles of individual DMEs in drug metabolism and toxicity, as well as characterizing the interactions of central DMEs with xenobiotics require reliable, practical and highly specific tools for sensing the activities of these enzymes in biological systems. In the last few decades, the scientists have developed a variety of optical substrates for sensing human DMEs, parts of them have been successfully used for studying target enzyme(s) in tissue preparations and living systems. Herein, molecular design principals and recent advances in the development and applications of optical substrates for human DMEs have been reviewed systematically. Furthermore, the challenges and future perspectives in this field are also highlighted. The presented information offers a group of practical approaches and imaging tools for sensing DMEs activities in complex biological systems, which strongly facilitates high-throughput screening the modulators of target DMEs and studies on drug/herb‒drug interactions, as well as promotes the fundamental researches for exploring the relevance of DMEs to human diseases and drug treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.